KR100642877B1 - 면역치료에 유용한 항원조성물 - Google Patents
면역치료에 유용한 항원조성물 Download PDFInfo
- Publication number
- KR100642877B1 KR100642877B1 KR1019990040180A KR19990040180A KR100642877B1 KR 100642877 B1 KR100642877 B1 KR 100642877B1 KR 1019990040180 A KR1019990040180 A KR 1019990040180A KR 19990040180 A KR19990040180 A KR 19990040180A KR 100642877 B1 KR100642877 B1 KR 100642877B1
- Authority
- KR
- South Korea
- Prior art keywords
- antigen
- composition
- solution
- mpl
- tyrosine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
아미노산 | 물 용해도 g/100㎖ |
글리신 | 25 |
알라닌 | 16.7 |
발린 | 8.9 |
루신 | 2.4 |
이소루신 | 4.1 |
메티오닌 | 3.4 |
프롤린 | 162 |
페닐알라닌 | 3.0 |
트립토판 | 1.1 |
세린 | 5.0 |
트레오닌 | 아주 큼 |
시스테인 | 아주 큼 |
티로신 | 0.04 |
아르파라긴 | 3.5 |
글루타민 | 3.7 |
아스파르트산 | 0.54 |
글루탐산 | 0.86 |
라이신 | 아주큼 |
아르기닌 | 15 |
히스티딘 | 4.2 |
Claims (18)
- (A) 항원 (B) 3 de-O-아실화 모노포스포릴 지질 A; 그리고 (C) 티로신 아미노산 또는 그 유도체나 염;을 포함하여 구성된 조성물.
- 제 1 항에 있어서, 상기 항원은 박테리아, 바이러스 또는 신생물질(종양)으로부터 유도됨을 특징으로하는 조성물.
- 제 1 항에 있어서, 상기 항원은 폴리펩타이드, 또는 항원 펩타이드를 암호화하며 폴리뉴클레오타이드 발현을 허용하는 조절 염기서열에 작동 연결된 폴리뉴클레오타이드를 포함하는 벡터 형태로 되어있음을 특징으로하는 조성물.
- 삭제
- 삭제
- 제 1 항에 있어서, 상기 조성물은 박테리아 감염, 바이러스 감염 또는 암에 대한 민감성을 치료하거나 방해 또는 감소시키기 위해 사용됨을 특징으로 하는 조성물.
- 의약적으로 수용가능한 운반제, 희석제 또는 부형제와 함께 제 1 항 내지 제 3 항 및 제 6 항중 어느 한 항에 나타낸 조성물을 포함하는 약학 조성물.
- 의약적으로 수용 가능한 운반제, 희석제 또는 부형제와 함께 제 1 항 내지 제 3항 및 제 6 항 중 어느 한 항에 나타낸 조성물을 포함하는 백신 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 강산 수용액에서 항원용액과 3 de-O-아실화 모노포스포릴 지질 A를 티로신 아미노산 또는 그 유도체나 염 용액과 용액 혼합물을 중화시키면서 혼합시키고, 이에따라 티로신 아미노산, 항원 및 보조제를 공침전시킴을 포함하는 제 1 항 내지 제 3 항 및 제 6 항중 어느 한 항에 의한 조성물 제조 방법.
- 제13항에 있어서, 나아가 약학적으로 수용가능한 운반제, 희석제 또는 부형제를 첨가하는 단계를 포함함을 특징으로 하는 방법.
- 제 2 항에 있어서, 상기 항원은 폴리펩타이드, 또는 항원 펩타이드를 암호화하며 폴리뉴클레오타이드 발현을 허용하는 조절 염기서열에 작동 연결된 폴리뉴클레오타이드를 포함하는 벡터 형태로 되어있음을 특징으로하는 조성물.
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9820525.5A GB9820525D0 (en) | 1998-09-21 | 1998-09-21 | Formulation |
GB9820525.5 | 1998-09-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000023273A KR20000023273A (ko) | 2000-04-25 |
KR100642877B1 true KR100642877B1 (ko) | 2006-11-13 |
Family
ID=10839197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990040180A KR100642877B1 (ko) | 1998-09-21 | 1999-09-17 | 면역치료에 유용한 항원조성물 |
Country Status (13)
Country | Link |
---|---|
US (2) | US6440426B1 (ko) |
EP (1) | EP0988862B1 (ko) |
JP (2) | JP4743928B2 (ko) |
KR (1) | KR100642877B1 (ko) |
AT (1) | ATE346610T1 (ko) |
AU (1) | AU766251B2 (ko) |
CA (1) | CA2282779C (ko) |
DE (1) | DE69934179T2 (ko) |
DK (1) | DK0988862T3 (ko) |
ES (1) | ES2277413T3 (ko) |
GB (2) | GB9820525D0 (ko) |
NZ (1) | NZ337885A (ko) |
PT (1) | PT988862E (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380376B1 (en) * | 1992-10-30 | 2002-04-30 | Iowa State University Research Foundation | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
GB9706957D0 (en) | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
JP2004504264A (ja) * | 2000-01-07 | 2004-02-12 | ユニバーシティ オブ シンシナティ | Th1又はth2リンパ球に制御される免疫応答の選択的活性化 |
GB0000891D0 (en) | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
US6858590B2 (en) * | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
ATE517184T1 (de) * | 2000-08-17 | 2011-08-15 | Tripep Ab | Hcv ns3/4a kodierende nukleinsäure |
US6680059B2 (en) * | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
ES2332402T5 (es) * | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
WO2002061003A1 (de) * | 2001-01-30 | 2002-08-08 | Schwan-Stabilo Schwanhäusser Gmbh & Co. | Markierungsflüssigkeit |
DE10125731A1 (de) * | 2001-05-17 | 2003-03-06 | A I D Autoimmun Diagnostika Gm | Darreichungsform von immunologischen Wirkstoffen |
SI2335725T1 (sl) | 2003-04-04 | 2017-01-31 | Genentech, Inc. | Visokokoncentrirane formulacije protiteles in proteinov |
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
US8333976B2 (en) * | 2003-08-28 | 2012-12-18 | Sandor Sipka | Processes for inhibiting development of allergic disease |
EP1843787B1 (en) * | 2005-01-28 | 2011-11-02 | North-West University | Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines |
EP1888751A2 (en) * | 2005-05-25 | 2008-02-20 | Tripep Ab | A hepatitis c virus non-structural ns3/4a fusion gene |
US20090214593A1 (en) * | 2007-08-16 | 2009-08-27 | Tripep Ab | Immunogen platform |
EP2185195A2 (en) * | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
SG174258A1 (en) * | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
MX2012010198A (es) | 2010-03-01 | 2012-10-03 | Bayer Healthcare Llc | Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi). |
GB201106802D0 (en) | 2011-04-21 | 2011-06-01 | Allergy Therapeutics Ltd | Process for preparing vaccine composition |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9962439B2 (en) | 2013-10-03 | 2018-05-08 | Nitto Denko Corporation | Injectable vaccine composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9706957D0 (en) * | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1128637A (en) * | 1966-09-13 | 1968-09-25 | Beecham Group Ltd | Influenza vaccine |
US3541201A (en) * | 1968-12-18 | 1970-11-17 | Ethan Alan Brown | Novel sodium chloride encapsulated injectionable substances |
GB1377074A (en) | 1971-07-13 | 1974-12-11 | Beecham Group Ltd | Process for preparing injectable compositions |
US4070455A (en) | 1974-02-16 | 1978-01-24 | Beecham Group Limited | Process for preparing injectable desensitizing compositions and products thereof in microparticle form |
GB1492973A (en) * | 1974-02-16 | 1977-11-23 | Beecham Group Ltd | Process for preparing injectable compositions |
EP0182442B2 (en) | 1978-12-22 | 1996-04-03 | Biogen, Inc. | Recombinant DNA molecules and their method of production |
US4258029A (en) | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5244663A (en) | 1987-01-28 | 1993-09-14 | Medibrevex | Therapeutic method against allergy |
FR2621916B1 (fr) * | 1987-10-19 | 1990-03-09 | Bioeurope | Derives de la l-tyrosine solubles dans l'eau et procede pour leur preparation |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB9106048D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccines |
US5338543A (en) * | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
EP0640347A1 (en) | 1992-03-03 | 1995-03-01 | Daiichi Pharmaceutical Co., Ltd. | Oral vaccine |
PT761231E (pt) | 1992-06-25 | 2000-06-30 | Smithkline Beecham Biolog | Composicao de vacina contendo adjuvantes |
AU6141094A (en) * | 1993-02-19 | 1994-09-14 | Smithkline Beecham Biologicals (Sa) | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
EP1175912A1 (en) * | 1993-03-23 | 2002-01-30 | SmithKline Beecham Biologics SA | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
US5958457A (en) * | 1993-04-22 | 1999-09-28 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
AU676340B2 (en) | 1993-05-25 | 1997-03-06 | Wyeth Holdings Corporation | Adjuvants for vaccines against respiratory syncytial virus |
CA2167691A1 (en) | 1993-08-27 | 1995-03-02 | Martin J. Blaser | Campylobacter jejuni antigens, and methods for their production and use |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5646115A (en) | 1994-10-07 | 1997-07-08 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
AU4977896A (en) | 1995-02-17 | 1996-09-04 | Immunotherapy, Inc. | Immunotherapy screening, prognosis, and treatment methods and compositions |
GB9508785D0 (en) * | 1995-04-29 | 1995-06-21 | Smithkline Beecham Plc | Novel compositions |
US5762943A (en) | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
US5973128A (en) | 1996-11-22 | 1999-10-26 | The Hospital For Sick Children Research And Development Lp | Glycolipid mimics and methods of use thereof |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
NZ338101A (en) | 1997-04-01 | 2002-03-28 | Corixa Corp | Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration |
AU7983198A (en) | 1997-06-23 | 1999-01-04 | Ludwig Institute For Cancer Research | Improved methods for inducing an immune response |
GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
GB9720585D0 (en) * | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
WO1999024577A1 (en) | 1997-11-10 | 1999-05-20 | Statens Serum Institut | NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS) |
GB9812613D0 (en) | 1998-06-11 | 1998-08-12 | Smithkline Beecham Biolog | Vaccine |
WO1999066043A1 (en) | 1998-06-12 | 1999-12-23 | Smithkline Beecham Biologicals S.A. | Recombinant production of toxoplasma sag1 antigen |
GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
ES2173679T3 (es) | 1999-01-27 | 2002-10-16 | Idea Ag | Inmunizacion/transporte transnasal con vehiculos altamente adaptables. |
EP2275133A1 (en) | 1999-02-26 | 2011-01-19 | Novartis Vaccines and Diagnostics, Inc. | Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
GB9909077D0 (en) | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
EP1173573A1 (en) | 1999-04-23 | 2002-01-23 | Pharmexa A/S | Method for down-regulating il5 activity |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
GB9924529D0 (en) | 1999-10-15 | 1999-12-15 | Smithkline Beecham Biolog | Novel compounds |
GB0000891D0 (en) | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
-
1998
- 1998-09-21 GB GBGB9820525.5A patent/GB9820525D0/en not_active Ceased
-
1999
- 1999-09-17 ES ES99307406T patent/ES2277413T3/es not_active Expired - Lifetime
- 1999-09-17 DK DK99307406T patent/DK0988862T3/da active
- 1999-09-17 JP JP26365299A patent/JP4743928B2/ja not_active Expired - Lifetime
- 1999-09-17 DE DE69934179T patent/DE69934179T2/de not_active Expired - Lifetime
- 1999-09-17 NZ NZ337885A patent/NZ337885A/xx not_active IP Right Cessation
- 1999-09-17 GB GB9922121A patent/GB2341801B/en not_active Expired - Lifetime
- 1999-09-17 CA CA2282779A patent/CA2282779C/en not_active Expired - Lifetime
- 1999-09-17 AU AU48777/99A patent/AU766251B2/en not_active Revoked
- 1999-09-17 PT PT99307406T patent/PT988862E/pt unknown
- 1999-09-17 EP EP99307406A patent/EP0988862B1/en not_active Expired - Lifetime
- 1999-09-17 AT AT99307406T patent/ATE346610T1/de active
- 1999-09-17 US US09/399,217 patent/US6440426B1/en not_active Expired - Lifetime
- 1999-09-17 KR KR1019990040180A patent/KR100642877B1/ko active IP Right Grant
-
2002
- 2002-08-02 US US10/211,388 patent/US7815920B2/en not_active Expired - Fee Related
-
2010
- 2010-08-27 JP JP2010190949A patent/JP2010265330A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9706957D0 (en) * | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
Also Published As
Publication number | Publication date |
---|---|
US20030007977A1 (en) | 2003-01-09 |
ATE346610T1 (de) | 2006-12-15 |
JP4743928B2 (ja) | 2011-08-10 |
CA2282779C (en) | 2011-02-01 |
GB2341801A (en) | 2000-03-29 |
DK0988862T3 (da) | 2006-12-27 |
EP0988862A3 (en) | 2001-06-20 |
AU4877799A (en) | 2000-06-08 |
DE69934179T2 (de) | 2007-04-19 |
ES2277413T3 (es) | 2007-07-01 |
US6440426B1 (en) | 2002-08-27 |
AU766251B2 (en) | 2003-10-09 |
US7815920B2 (en) | 2010-10-19 |
KR20000023273A (ko) | 2000-04-25 |
JP2000103745A (ja) | 2000-04-11 |
DE69934179D1 (de) | 2007-01-11 |
JP2010265330A (ja) | 2010-11-25 |
EP0988862B1 (en) | 2006-11-29 |
GB9922121D0 (en) | 1999-11-17 |
PT988862E (pt) | 2007-01-31 |
CA2282779A1 (en) | 2000-03-21 |
EP0988862A2 (en) | 2000-03-29 |
GB2341801B (en) | 2003-10-29 |
GB9820525D0 (en) | 1998-11-11 |
NZ337885A (en) | 2001-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100642877B1 (ko) | 면역치료에 유용한 항원조성물 | |
JP2010265330A6 (ja) | 処方物 | |
US4816253A (en) | Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
SK11295A3 (en) | Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them | |
CA2397359C (en) | Composition of antigen and glycolipid adjuvant sublingual administration | |
JP2003502388A5 (ko) | ||
US4567041A (en) | Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
EP1768696A2 (en) | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus | |
WO1993002706A1 (en) | Self-adjuvanting peptide vaccine delivery system and production thereof | |
AU774649B2 (en) | Vaccine preparations containing attenuated toxin | |
KR100549557B1 (ko) | 알레르겐 조성물 | |
AU2003268581B2 (en) | Formulation | |
EP2514438B1 (en) | ADJUVANT CONTAINING ß-HEMATIN | |
CA3012417C (en) | Amyloid conjugate and uses and methods thereof | |
RU2021817C1 (ru) | Способ получения вакцины против холеры | |
WO2021207303A1 (en) | Immune stimulation against coronavirus infections | |
AU657565B2 (en) | Self-adjuvanting peptide vaccine delivery system and production thereof | |
WO2012070974A1 (ru) | Вакцины с повышенной иммуногенностью и способы их получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121009 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131001 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141006 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151029 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160929 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20181001 Year of fee payment: 13 |